cor2ed
engage checkpoint medical linkedin twitter
bg

Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy

Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy

Dr. Judith Balmaña, Dr. Rebecca Dent, Prof. Simon Boulton, Prof. Sibylle Loibl, Prof. Eric Pujade-Lauraine, Prof. Charlie Gourley, Dr. Violeta Serra, Prof. Jonathan A. Ledermann

Published in the Journal of Clinical Oncology, a review paper authored by a multidisciplinary group of international experts in DNA Damage Response (DDR) and PARP inhibition
Portrait of Judith Balmaña
Dr. Judith Balmaña

Medical Oncologist

Vall d'Hebron University Hospital

Spain

Portrait of Rebecca Dent
Dr. Rebecca Dent

Medical Oncologist

National Cancer Center Singapore

Singapore

Portrait of Simon Boulton
Prof. Simon Boulton

Senior Scientist

Francis Crick Institute

United Kingdom (UK)

Portrait of Sibylle Loibl
Prof. Sibylle Loibl

Medical Oncologist

German Breast Group GmbH

Germany

Portrait of Eric Pujade-Lauraine
Prof. Eric Pujade-Lauraine

Gynaecologic Oncologist

Hôpital Hôtel-Dieu

France

Portrait of Charlie Gourley
Prof. Charlie Gourley

Medical Oncologist

CRUK Edinburgh Centre, Nicola Murray Centre for Ovarian Cancer Re...

United Kingdom (UK)

Portrait of Violeta Serra
Dr. Violeta Serra

Senior Scientist

Vall d'Hebron Institute of Oncology

Spain

Portrait of Jonathan A. Ledermann
Prof. Jonathan A. Ledermann

Medical Oncologist

UCL Cancer Institute

United Kingdom (UK)

preview next

time Now Published | open 10 min

temporal

download resources

I agree that this educational programme:

Was valuable to me:

1/3

Other programmes of interest

Other programmes developed by Dr. Judith Balmaña

Other programmes developed by Dr. Rebecca Dent

Other programmes developed by Prof. Simon Boulton

Other programmes developed by Prof. Eric Pujade-Lauraine

Other programmes developed by Prof. Charlie Gourley

Other programmes developed by Dr. Violeta Serra

Other programmes developed by Prof. Jonathan A. Ledermann